Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

ImmunoPrecise Antibodies Ltd. (V:IPA)

Business Focus: Biopharmaceuticals

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for IPA within the last 6 months
See all filings within the past 6 months

Company News

Jan 06, 2021 22:34 ET
ImmunoPrecise Antibodies Announces Grant of Stock Options
IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that its board of directors has approved the grant of 25,000 stock options (the “Options”) under its stock option plan to acquire up to an aggregate of 25,000 common shares in the capital of IPA (“Common Shares”). Each of the five non-executive directors of IPA has been granted 5,000 Options.
Read full article
Jan 06, 2021 07:45 ET
ImmunoPrecise Antibodies to Participate in January Conferences
IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (Nasdaq: IPA) (TSXV: IPA) a leader in full-service, therapeutic antibody discovery, today announced that Dr. Jennifer Bath, ImmunoPrecise’s Chief Executive Officer, will participate in a pre-recorded presentation through the H.C. Wainwright BioConnect 2021 Conference, and management will host one-on-one meetings with investors through the Stern IR Virtual Corporate Access Event, both taking place January 11-14, 2021.
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Dec 31, 202040,795-9,823
Dec 15, 202050,61820,437
Nov 30, 202030,181-6,916
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Immunoprecise Antibodies Ltd, formerly Tanqueray Exploration Ltd, is a Canada-based supplier of custom hybridoma development services. The Company's geographical segments include United States of America and Canada. It offers products, such as antibodies and hybridoma licensing. It offers various services, such as ImmunoProtect, Monoclonal Development, Polyclonal Development, Antibody Protection, Peptide Production and Cryopreservation Services. Its antibody products include IPA006A, IPA006B and IPA006F, which it offers to the research and industrial community. Its hybridoma licensing products include Anti-Human P38a (MAPKinase) Monoclonal Antibody Hybridoma Cell Line and Anti-Acetylated Lysine Monoclonal Antibody Hybridoma Cell Line. It offers cryopreservation storage service for the secure storage of users' valuable biological materials, including hybridoma clones, plasmid constructs and cell lines. It also offers both peptide synthesis and protein carrier conjugation services.

See business summary



Search (past week) for $IPA.CA IPA.V